Fortune 50 Pharmaceutical Company Preferred Stock Offering

Our firm represented the venture arm of a Fortune 50 pharmaceutical company in a $17 million convertible preferred stock investment in a healthcare IT company.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.